Journal List > J Korean Acad Oral Health > v.37(4) > 1057568

TOOLS
Choi, Kim, Kim, Lee, Yang, and Song: Polycan-calcium gluconate complex improves gingival health
Original Article

J Korean Acad Oral Health 2013;37(4):175-179.

Published online: 12 December 2013

DOI: https://doi.org/10.11149/jkaoh.2013.37.4.175

Polycan-calcium gluconate complex improves gingival health

Youn-Hee Choi1, Ji-Hye Kim1, Jae-Young Kim2, Young-Kyun Lee2, Hae-Young Yang1, Keun-Bae Song1

1Department of Preventive Dentistry, Kyungpook National University School of Dentistry, Daegu, Korea

2Department of Oral Biochemistry, Kyungpook National University School of Dentistry, Daegu, Korea

Corresponding Author: Keun-Bae Song Department of Preventive Dentistry, Kyungpook National University School of Dentistry, 2177 Dalgubeol-daero, Jung-gu, Daegu 700-412, Korea Tel: +82-53-660-6870 Fax: +82-53-423-2947 E-mail: kbsong@knu.ac.kr

Received 28 October 2013       Revised 22 November 2013       Accepted 6 December 2013

Copyright © 2013 Journal of Korean Academy of Oral Health

This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Objectives

The aim of this study was to examine the effect of a Polycan-calcium gluconate complex on gingival health.

Methods

Forty-one subjects with mild periodontitis (≥40 years) were divided into two groups: the placebo and test product (Polycan-calcium gluconate complex twice a day for 4 weeks) groups. Oral examination was performed and gingival crevicular fluid (GCF) was collected from each subject at baseline and after 4 weeks. Interleukin (IL)-1β level in the GCF was determined using enzyme-linked immunosorbent assay.

Results

Pocket depth and plaque index were significantly decreased in the test group at 4 weeks. The level of IL-1β and plaque index of the treatment group was significantly lower than of the placebo group.

Conclusions

Based on the above results, Polycan-calcium gluconate complex may inhibit plaque accumulation in the mouth and may have a negative correlation with the level of inflammatory biomarkers. Consequently, gingival health was significantly improved by polycan-calcium gluconate complex.

Keywords: β-glucan, Calcium gluconate, Gingival health, Polycan

References

1. Pihlstrom BL, Michalowicz BS, Johnson NW. Periodontal diseases. Lancet. 2005; 366:1809–1820.
crossref
2. Ministry of Health and Welfare. 2011 National Health Insurance Statistical Yearbook. Seoul: Ministry of Health & Welfare;2011. p. 555–617.
3. Lee SY, Jung YH, Kim KH, Yang BK, Han SB, Chung CP, et al. Matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in gingival crevicular fluids of periodontitis patients. J Korean Acad periodontol. 2004; 34:139–148.
crossref
4. Dongari-Bagtzoglou AI, Ebersole JL. Production of inflammatory mediators and cytokines by human gingival fibroblasts following bacterial challenge. J Periodontal Res. 1996; 31:90–98.
crossref
5. Birkedal-Hansen H. Role of cytokine and inflammatory mediators in tissue destruction. J Periodontal Res. 1993; 28:500–510.
6. Hernández Ríos M, Sorsa T, Obregón F, Tervahartiala T, Valenzuela MA, Pozo P, et al. Proteolytic roles of matrix metalloproteinase (MMP)-13 during progression of chronic periodontitis: initial evidence for MMP-13/MMP-9 activation cascade. J Clin Periodontol. 2009; 36:1011–1017.
crossref
7. Bonesvoll P. Oral pharmacology of chlorhexidine. J Clin Periodon-tol. 1977; 4:49–65.
crossref
8. Khoo JG, Newman HN. Subgingival plaque control by a simplified oral hygiene regime plus local chlorhexidine or metronidazole. J Periodontal Res. 1983; 18:607–619.
crossref
9. Chan GCF, Chan WK, Sze DMY. The effects of β-glucan on human immune and cancer cells. J Hematol Oncol. 2009; 2:1–11.
crossref
10. Song HS, Moon KY. In vitro antioxidant activity profiles of β-glucan isolated from yeast Saccharomayces cerevisiae and mutant Saccharomayces cerevisiae IS2. Food Sci Biotechnol. 2006; 15:437–440.
11. Kogan G, Pajtinka M, Babioncova M, Miadokova E, Rauko P, Sla-menova D, et al. Yeast cell wall polysaccharides as antioxidants and antimutagens: can they fight cancer? Neoplasma. 2008; 55:387–393.
12. Novak M, Vetvicka V. Beta-glucans, history, and the present: immunomodulatory aspects and mechanisms of action. J Immuno-toxicol. 2008; 5:47–57.
13. Abdel-Salam OM, Baiuomy AR, El-batran S, Arbid MS. Evaluation of the anti-inflammatory, anti-nociceptive and gastric effects of Ginkgo biloba in the rat. Pharmacol Res. 2004; 49:133–142.
crossref
14. Shin HD, Yang KJ, Park BR, Son CW, Jang HJ, Ku SK. Antios-teoporotic effect of polycan, beta-glucan from Aureobasidium, in ovariectomized osteoporotic mice. Nutrition. 2007; 23:853–860.
15. Song HB, Park DC, Do GM, Hwang SL, Lee WK, Kang HS, et al. Effect of exopolymers of Aureobasidium pullulans on improving osteoporosis induced in ovariectomized mice. J Microbiol Biotechnol. 2006; 16:37–45.
16. Queiroz LS, Nascimento MS, Cruz AK, Castro AJ, Moura Mde F, Baseia IG, et al. Glucans from the Caripia montagnei mushroom present anti-inflammatory activity. Int Immunopharmacol. 2010; 10:34–42.
crossref
17. Kim YS, Kang SJ, Kim JW, Cho HR, Moon SB, Kim KY, et al. Effects of Polycan, a β-glucan, on experimental periodontitis and alveolar bone loss in Sprague-Dawley rats. J Periodontal Res. 2012; 47:800–810.
crossref
18. Bracken WM, Cuppage F, McLaury RL, Kirwin C, Klaassen CD. Comparative effectiveness of topical treatments for hydrofluoric acid burns. J Occup Med. 1985; 27:733–739.
19. Cavallini M, de Boccard F, Corsi MM, Fassati LR, Baruffaldi Preis FW. Serum pro-inflammatory cytokines and chemical acid burns in rats. Ann Burns Fire Disasters. 2004; 17:84–87.
20. Karnad AS, Patil PA, Majagi SI. Calcium enhances anti-inflammatory activity of aspirin in albino rats. Indian J Pharmacol. 2006; 38:397–402.
crossref
21. Ku SK, Cho HR, Sung YS, Kang SJ, Lee YJ. Effects of calcium gluconate on experimental periodontitis and alveolar bone loss in rats. Basic Clin Pharmacol Toxicol. 2011; 108:241–250.
crossref
22. Silness J, Löe H. Periodontal disease in pregnancy.II. Correlation between oral hygiene and periodontal condition. Acta Odontol Scand. 1964; 22:121–135.
23. Ainslie PT, Caffesse RG. A biometric evaluation of gingival curettage (II). Quintessence Int Dent Dig. 1981; 12:609–614.
24. Cercek JF, Kiger RD, Garrett S, Egelberg J. Relative effects of plaque control and instrumentation on the clinical parameters of human periodontal disease. J Clin Periodontol. 1983; 10:46–56.
crossref
25. Figueredo CM, Ribeiro MS, Fischer RG, Gustafsson A. Increased interleukin-1β concentration in gingival crevicular fluid as a characteristic of periodontitis. J Periodontol. 1999; 70:1457–1463.
crossref
26. Gamonal J, Acevedo A, Bascones A, Jorge O, Silva A. Level of interleukin-1β, -8, and -10 and RANTES in gingival crevicular fluid and cell populations in adult periodontitis patients and the effect of periodontal treatment. J Periodontol. 2000; 71:1535–1545.
27. Rawlinson A, Dalati MH, Rahman S, Walsh TF, Fairclough AL. Interleukin-1 and IL-1 receptor antagonist in gingival crevicular fluid. J Clin Periodontol. 2000; 27:738–743.
crossref

Fig. 1.
Comparison of IL-1β in the gingival crevicular fluid between the two groups by ELISA. Triangle and circle indicate IL-1β level of each subject. P-value obtained from Mann-Whitney test.
jkaoh-37-175f1.tif
Table 1.
General characteristics of study subject
Placebo(N=21) Treatment(N=20) P-value*
Gender No. (%)
Male 2 (9.5) 1 (5) 0.519
Female 19 (90.5) 19 (95)
Household income‡
(1,0000 won per month)
<100 15 (71.4) 10 (50.0) 0.212
100-199 3 (14.3) 4 (20.0)
≥200 3 (14.3) 5 (25.0)
Education (yrs)
≤9 12 (57.1) 11 (55.0) 0.361
≥10 9 (42.9) 9 (45.0)
Job‡
Unemployed 15 (71.4) 12 (60.0) 0.652
Other else 6 (28.6) 7 (40.0)
Mean±SD
Age 64.19±10.48 59.20±8.97 0.110†
Height (cm) 157.18± 5.85 155.95±4.06 0.454†
Weight (kg) 60.45± 9.24 56.46±6.40 0.131†
Body Mass Index (kg/m2) 19.21± 2.69 18.10±2.02 0.160†

*P-value obtained from χ2-test.†The data were analysed by Mann-Whitney test.‡There were missing values.

Table 2.
Oral health characteristics of study subject
Placebo(N=21) Treatment(N=20) P-value*
Brushing frequency 3.52±0.81‡ 3.40±0.75‡ 0.617†
Time of brushing No. (%)
After breakfast
Yes 16 (76.2) 15 (75.0) 0.857
No 5 (23.8) 5 (25.0)
After lunch
Yes 9 (42.9) 10 (50.0) 0.442
No 12 (57.1) 10 (50.0)
After dinner
Yes 15 (71.4) 11 (55.0) 0.222
No 6 (28.6) 9 (45.0)
Before bedtime
Yes 5 (23.8) 6 (30.0) 0.462
No 16 (76.2) 14 (70.0)
Use of oral hygiene auxiliaries
Yes 12 (60.0) 10 (50.0) 0.103
No 8 (40.0) 10 (50.0)
Regular dental check-ups forthe last one year
Yes 9 (42.9) 7 (35.0) 0.423
No 12 (57.1) 13 (65.0)
Periodontal treatment experiencefor the last one year
Yes 5 (23.8) 7 (35.0) 0.329
No 16 (76.2) 13 (65.0)

*P-value obtained from χ2-test.†The data were analysed by Mann-Whitney test.‡values are mean±SD.

Table 3.
Mean changes of clinical parameters according to times by groups clinical parameters in the control and treatment groups at baseline, 4 weeks
Placebo (N=21) Treatment (N=20)
Baseline After 4 weeks P-value* Baseline After 4 weeks P-value*
Pocket depth (mm) 1.58±0.31 1.47±0.34 0.008 1.58±0.31 1.48±0.28 0.035
Clinical attachment loss (mm) 0.45±0.45 0.44±0.44 0.814 0.37±0.35 0.37±0.34 0.677
Gingival index 1.30±0.38 1.19±0.28 0.201 1.20±0.31 1.06±0.29 0.058
Plaque index 1.46±0.43 1.33±0.31 0.139 1.41±0.45 1.12±0.34† 0.015
Bleeding index 5.33±4.56 3.62±2.91 0.072 3.90±2.90 2.85±2.30 0.065

Values are mean±SD. *P-value obtained from wilcoxon's signed rank test.

† The data were analysed by Mann-Whitney test.

TOOLS
Similar articles